Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Nov 22;91(24):11502–11506. doi: 10.1073/pnas.91.24.11502

A low-affinity estrogen-binding site in pregnant rat uteri: analysis and partial purification.

W G Gray 1, E E Biswas 1, N Bashirelahi 1, S B Biswas 1
PMCID: PMC45259  PMID: 7526397

Abstract

We have identified a low-affinity (type II) estrogen-binding site (EBS) that is expressed at high levels during pregnancy in rat uteri. Although this activity was detectable in nonpregnant rat uteri, it was present in amounts (0.094 pmol/g of uteri) that were severalfold lower than the high-affinity type I estrogen receptor (0.57 pmol/g of uteri). During pregnancy, at 19-20 days of gestation, the low-affinity type II EBS became the major (> or = 88%) estrogen-binding site in rat uteri. The increase in the level of low-affinity EBS (7.9 pmol/g) in uteri was approximately 85-fold with an approximately 20-fold increase in the specific activity (0.39 pmol/mg) of this form, whereas the high-affinity form remained relatively unchanged. We report here a method of purification of type II EBS from pregnant rat uteri and present an analysis of its DNA and steroid-binding properties. Estradiol-binding studies and Scatchard analysis showed that the type II EBS had an apparent estradiol-binding affinity of > or = 24 nM. Gel filtration and SDS/PAGE analysis indicated that the type II EBS was a monomeric 73-kDa protein. The estradiol binding remained apparently uninhibited in the presence of a large excess of tamoxifen, nafoxidine, or dihydrotestosterone. Estradiol, diethylstilbestrol, and quercitin (a type II EBS-specific inhibitor) competed efficiently. The purified low-affinity EBS did not have sequence-specific DNA-binding activity with the estrogen-responsive element, which indicated that it differs in function from the type I estrogen receptor.

Full text

PDF
11502

Images in this article

11503Image
on p.11503
11504Image
on p.11504
11505Image
on p.11505

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biswas E. E., Stefanec M. J., Biswas S. B. Molecular cloning of a gene encoding an ARS binding factor from the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6689–6692. doi: 10.1073/pnas.87.17.6689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biswas S. B., Biswas E. E. ARS binding factor I of the yeast Saccharomyces cerevisiae binds to sequences in telomeric and nontelomeric autonomously replicating sequences. Mol Cell Biol. 1990 Feb;10(2):810–815. doi: 10.1128/mcb.10.2.810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Burch J. B., Evans M. I., Friedman T. M., O'Malley P. J. Two functional estrogen response elements are located upstream of the major chicken vitellogenin gene. Mol Cell Biol. 1988 Mar;8(3):1123–1131. doi: 10.1128/mcb.8.3.1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chae K., Johnston S. H., Korach K. S. Multiple estrogen binding sites in the uterus: stereochemistry of receptor and non-receptor binding of diethylstilbestrol and its metabolites. J Steroid Biochem Mol Biol. 1991 Jan;38(1):35–42. doi: 10.1016/0960-0760(91)90398-o. [DOI] [PubMed] [Google Scholar]
  6. Densmore C. L., Markaverich B. M., O'Malley B. W., Clark J. H. Characterization and partial purification of an estrogen type II binding site in chick oviduct cytosol. Biochemistry. 1989 Sep 19;28(19):7788–7796. doi: 10.1021/bi00445a039. [DOI] [PubMed] [Google Scholar]
  7. Eriksson H., Upchurch S., Hardin J. W., Peck E. J., Jr, Clark J. H. Heterogeneity of estrogen receptors in the cytosol and nuclear fractions of the rat uterus. Biochem Biophys Res Commun. 1978 Mar 15;81(1):1–7. doi: 10.1016/0006-291x(78)91622-4. [DOI] [PubMed] [Google Scholar]
  8. Garai J., Tiller A. A., Clark J. H. Tyrosinase-like polypeptides in the uterus and in the central nervous system of rats. Steroids. 1992 Apr;57(4):183–188. doi: 10.1016/0039-128x(92)90006-u. [DOI] [PubMed] [Google Scholar]
  9. Gorski J., Hansen J. C., Welshons W. V. Estrogen receptors as nuclear proteins. Adv Exp Med Biol. 1987;230:13–29. doi: 10.1007/978-1-4684-1297-0_2. [DOI] [PubMed] [Google Scholar]
  10. Greco T. L., Gorski J. Serum and monohydroxytamoxifen inhibit progesterone receptor concentrations in primary rat uterine cells grown in serum-free medium. Endocrinology. 1989 Jun;124(6):2837–2843. doi: 10.1210/endo-124-6-2837. [DOI] [PubMed] [Google Scholar]
  11. Jost J. P., Seldran M., Geiser M. Preferential binding of estrogen-receptor complex to a region containing the estrogen-dependent hypomethylation site preceding the chicken vitellogenin II gene. Proc Natl Acad Sci U S A. 1984 Jan;81(2):429–433. doi: 10.1073/pnas.81.2.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klein-Hitpass L., Schorpp M., Wagner U., Ryffel G. U. An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell. 1986 Sep 26;46(7):1053–1061. doi: 10.1016/0092-8674(86)90705-1. [DOI] [PubMed] [Google Scholar]
  13. Klein-Hitpass L., Tsai S. Y., Greene G. L., Clark J. H., Tsai M. J., O'Malley B. W. Specific binding of estrogen receptor to the estrogen response element. Mol Cell Biol. 1989 Jan;9(1):43–49. doi: 10.1128/mcb.9.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koike S., Sakai M., Muramatsu M. Molecular cloning and characterization of rat estrogen receptor cDNA. Nucleic Acids Res. 1987 Mar 25;15(6):2499–2513. doi: 10.1093/nar/15.6.2499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kumar V., Green S., Stack G., Berry M., Jin J. R., Chambon P. Functional domains of the human estrogen receptor. Cell. 1987 Dec 24;51(6):941–951. doi: 10.1016/0092-8674(87)90581-2. [DOI] [PubMed] [Google Scholar]
  16. Kumar V., Green S., Staub A., Chambon P. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J. 1986 Sep;5(9):2231–2236. doi: 10.1002/j.1460-2075.1986.tb04489.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Környei J. L., Csermely T., Keller G., Vértes M. Nuclear type II estradiol binding sites and type I estrogen receptors in human endometrial cancer: a 5-year follow-up study. Gynecol Oncol. 1993 Jan;48(1):94–103. doi: 10.1006/gyno.1993.1015. [DOI] [PubMed] [Google Scholar]
  18. Lopes M. T., Liberato M. H., Widman A., Brentani M. M. Occupied and unoccupied type II estrogen binding sites in human breast cancer. J Steroid Biochem. 1987 Feb;26(2):219–226. doi: 10.1016/0022-4731(87)90075-6. [DOI] [PubMed] [Google Scholar]
  19. Markaverich B. M., Roberts R. R., Finney R. W., Clark J. H. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei. J Biol Chem. 1983 Oct 10;258(19):11663–11671. [PubMed] [Google Scholar]
  20. Marsigliante S., Biscozzo L., Barker S., Leo G., Puddefoot J. R., Vinson G. P., Storelli C. Type II oestrogen binding site is associated with the major 4S oestrogen receptor isoform in breast tumours. J Steroid Biochem Mol Biol. 1992 Aug;42(7):777–781. doi: 10.1016/0960-0760(92)90118-3. [DOI] [PubMed] [Google Scholar]
  21. Marsigliante S., Puddefoot J. R., Barker S., Gledhill J., Vinson G. P. Discrepancies between antibody (EIA) and saturation analysis of oestrogen receptor content in breast tumour samples. J Steroid Biochem Mol Biol. 1990 Dec 10;37(5):643–648. doi: 10.1016/0960-0760(90)90346-m. [DOI] [PubMed] [Google Scholar]
  22. Maurer R. A., Notides A. C. Identification of an estrogen-responsive element from the 5'-flanking region of the rat prolactin gene. Mol Cell Biol. 1987 Dec;7(12):4247–4254. doi: 10.1128/mcb.7.12.4247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McLeod J. F., Cooke N. E. The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem. 1989 Dec 25;264(36):21760–21769. [PubMed] [Google Scholar]
  24. Nishi S., Matsue H., Yoshida H., Yamaoto R., Sakai M. Localization of the estrogen-binding site of alpha-fetoprotein in the chimeric human-rat proteins. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3102–3105. doi: 10.1073/pnas.88.8.3102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Panko W. B., Watson C. S., Clark J. H. The presence of a second, specific estrogen binding site in human breast cancer. J Steroid Biochem. 1981 Dec;14(12):1311–1316. doi: 10.1016/0022-4731(81)90337-x. [DOI] [PubMed] [Google Scholar]
  26. Ponglikitmongkol M., Green S., Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988 Nov;7(11):3385–3388. doi: 10.1002/j.1460-2075.1988.tb03211.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Savu L., Benassayag C., Vallette G., Christeff N., Nunez E. Mouse alpha 1-fetoprotein and albumin. A comparison of their binding properties with estrogen and fatty acid ligands. J Biol Chem. 1981 Sep 25;256(18):9414–9418. [PubMed] [Google Scholar]
  28. Scambia G., Ranelletti F. O., Benedetti Panici P., Piantelli M., Bonanno G., De Vincenzo R., Ferrandina G., Pierelli L., Capelli A., Mancuso S. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol. 1991;28(4):255–258. doi: 10.1007/BF00685531. [DOI] [PubMed] [Google Scholar]
  29. Scambia G., Ranelletti F. O., Benedetti Panici P., Piantelli M., Rumi C., Battaglia F., Larocca L. M., Capelli A., Mancuso S. Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids. Int J Cancer. 1990 Dec 15;46(6):1112–1116. doi: 10.1002/ijc.2910460627. [DOI] [PubMed] [Google Scholar]
  30. Stack G., Korach K., Gorski J. Relative mitogenic activities of various estrogens and antiestrogens. Steroids. 1989 Aug;54(2):227–243. doi: 10.1016/0039-128x(89)90096-2. [DOI] [PubMed] [Google Scholar]
  31. Swaneck G. E., Alvarez J. M., Sufrin G. Multiple species of estrogen binding sites in the nuclear fraction of the rat prostate. Biochem Biophys Res Commun. 1982 Jun 30;106(4):1441–1447. doi: 10.1016/0006-291x(82)91275-x. [DOI] [PubMed] [Google Scholar]
  32. Syne J. S., Markaverich B. M., Clark J. H., Panko W. B. Estrogen binding sites in the nucleus of normal and malignant human tissue: optimization of an exchange assay for the measurement of specific binding. Cancer Res. 1982 Nov;42(11):4443–4448. [PubMed] [Google Scholar]
  33. Walter P., Green S., Greene G., Krust A., Bornert J. M., Jeltsch J. M., Staub A., Jensen E., Scrace G., Waterfield M. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A. 1985 Dec;82(23):7889–7893. doi: 10.1073/pnas.82.23.7889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Williams D., Gorski J. Equilibrium binding of estradiol by uterine cell suspensions and whole uteri in vitro. Biochemistry. 1974 Dec 31;13(27):5537–5542. doi: 10.1021/bi00724a013. [DOI] [PubMed] [Google Scholar]
  35. Yu M., Cates J., Leav I., Ho S. M. Heterogeneity of [3H]estradiol binding sites in the rat prostate: properties and distribution of type I and type II sites. J Steroid Biochem. 1989 Sep;33(3):449–457. doi: 10.1016/0022-4731(89)90336-1. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES